Hyperlipemia

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Rosuvastatin 10mg/d groupPhase 41 trial
Active Trials
NCT02593487Unknown300Est. Jun 2017
Suzhou Ribo Life Science Company
1 program
1
RBD7022Phase 11 trial
Active Trials
NCT05912296CompletedEst. Mar 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaRosuvastatin 10mg/d group
Suzhou Ribo Life Science CompanyRBD7022

Clinical Trials (2)

Total enrollment: 300 patients across 2 trials

NCT02593487AstraZenecaRosuvastatin 10mg/d group

Effect of Rosuvastatin Therapy on HDL2 Level

Start: Nov 2015Est. completion: Jun 2017300 patients
Phase 4Unknown

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Start: May 2023Est. completion: Mar 2025
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space